• +41 91 682 20 40
  • info@elixi-int.com
  • Reserved Area
    • Login
    • Register
    • Request Document
    • Send Document
logo
  • Home
  • About Us
  • Services
  • Quality
  • News
  • Case Studies
  • Contact

Let's talk

info@yourwebsite.com
+1 (555) 123-4567

  • Search

Elixi

29 August 2020

Roche announces FDA approval of FoundationOne Liquid CDx, a comprehensive pan-tumour liquid biopsy test


0 Comments4 Minutes

14 August 2020

Vaginal ring to reduce the risk of HIV infection for women in non-EU countries with high disease burden


0 Comments4 Minutes

14 August 2020

Rozlytrek, Roche’s first tumour-agnostic therapy, approved in Europe for people with NTRK fusion-positive solid tumours and for people with ROS1-positive advanced non-small cell lung cancer


0 Comments4 Minutes

24 July 2020

Blenrep (belantamab mafodotin), new option for the treatment of relapsed and refractory multiple myeloma


0 Comments3 Minutes

14 July 2020

Inqovi (decitabine and cedazuridine), new Therapy for Myelodysplastic Syndromes (MDS) That Can Be Taken at Home


0 Comments2 Minutes

7 July 2020

Rukobia (fostemsavir), a new antiretroviral medication for patients who have run out of HIV treatment options


0 Comments3 Minutes

12 June 2020

Uplizna (inebilizumab-cdon)Therapy for Neuromyelitis Optica Spectrum Disorder Offers Patients Additional Treatment Option


0 Comments4 Minutes

6 June 2020

FDA Approves Merck’s RECARBRIO (imipenem, cilastatin, and relebactam) for the Treatment of Adults with Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP)


0 Comments3 Minutes

29 May 2020

FDA Approves Oriahnn (an estrogen and progestin combination product consisting of elagolix, estradiol and norethindrone acetate)to Treat Heavy Menstrual Bleeding Associated with Fibroids in Women


0 Comments6 Minutes

19 May 2020

Qinlock (ripretinib) is the First Drug for Fourth-Line Treatment of Advanced Gastrointestinal Stromal Tumors


0 Comments4 Minutes

  • 1
  • …
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • 13